Skip to content
Ejaculation.org

Treatment

Premature Ejaculation Treatment Guidelines: AUA, EAU and ISSM Explained

Premature ejaculation treatment guidelines from the AUA/SMSNA, EAU and ISSM compared: definitions, diagnosis and first-line treatment, in plain English.

Short answer

The three main premature ejaculation treatment guidelines, from the AUA/SMSNA in the US, the European Association of Urology and the International Society for Sexual Medicine, agree on the basics: diagnose from your history, treat erection problems or other causes first, and offer medication, numbing sprays and behavioral therapy, often combined. They differ mainly on which medicine comes first.

Updated · sources listed at the end of this page

By The Ejaculation.org Editorial TeamUpdated 9 min read

Key takeaways

  • Three guidelines shape premature ejaculation care: the AUA/SMSNA guideline (US), the European Association of Urology (EAU) guidelines and the International Society for Sexual Medicine (ISSM) guideline.
  • All three diagnose PE from a medical and sexual history, using a self-estimated time to ejaculation, and none recommends routine laboratory tests.
  • First-line medicine differs: the US guideline lists daily SSRIs, on-demand clomipramine or dapoxetine and numbing products; the EAU recommends dapoxetine or a lidocaine–prilocaine spray for lifelong PE.
  • No medicine is FDA-approved for PE, so US prescribing is off-label; dapoxetine is approved in many other countries.
  • All three say combining behavioral or psychological therapy with medication may work better than either alone, and none supports surgery outside research.

Premature ejaculation treatment guidelines are the formal recommendations doctors follow when they assess and treat premature ejaculation (PE). Three matter most: the AUA/SMSNA guideline from the American Urological Association and the Sexual Medicine Society of North America, the European Association of Urology (EAU) guidelines, and the International Society for Sexual Medicine (ISSM) guideline. They agree on the essentials, diagnosis from your history, treating erection problems or other causes first, and medication, numbing products and behavioral therapy as the main tools, but they rank the medicines differently.

This page compares them side by side, with a plain-English column, so you know what a doctor is likely to suggest and why. It sits in our premature ejaculation treatment section; for the broader picture, start with the complete guide to premature ejaculation.

Which organizations publish premature ejaculation guidelines?

Three bodies publish the guidelines most doctors use. Each grades its recommendations differently, which is worth knowing when you read them.

GuidelineVersionScopeHow recommendations are graded
AUA/SMSNA: Disorders of EjaculationReleased 2020, journal publication 2022PE and delayed ejaculation, US practiceStrong, Moderate or Conditional, with evidence grade A to C; or Clinical Principle / Expert Opinion
EAU: Sexual and Reproductive HealthUpdated yearly; 2025 update summarized in European UrologyPE among other male sexual health topics, European practiceStrong or Weak
ISSM: Diagnosis and Treatment of PE2014 updatePE only, international, written for family doctors and specialistsLevel of evidence, from 1a (strongest) downward

The AUA/SMSNA guideline drew on a systematic review of 8 systematic reviews and 59 individual studies (Shindel et al., 2022). The EAU panel updated its review with research from 2021 to 2024 (Salonia et al., 2025). The ISSM's 2014 update came from a multidisciplinary panel that met in 2013 (Althof et al., 2014); it is the oldest of the three, and its own authors recommended a revision every four years.

How do the guidelines define premature ejaculation?

All three define PE by three features together: a short time to ejaculation, poor control and personal distress. They differ on the time.

Lifelong PEAcquired PEIn plain English
ISSMWithin about 1 minute of penetration, from the first sexual experiencesA bothersome drop, often to about 3 minutes or lessTime alone is not enough; you also need low control and distress
EAUAdopts the ISSM definitionAdopts the ISSM definitionSame as above
AUA/SMSNAWithin about 2 minutes, present since sexual debutLatency markedly reduced compared with beforeA slightly wider net for lifelong PE

Sources: (Serefoglu et al., 2014), (Salonia et al., 2025), and the AUA/SMSNA guideline statements 1 and 2 (AUA).

The EAU adds two patterns that are not disorders: "variable PE", which it calls "a normal variation in sexual performance", and "subjective PE", where a man feels too quick despite a normal time (EAU). The ISSM recommends that men with the variable pattern be educated and reassured rather than treated. Our page on lifelong vs acquired PE helps you work out which applies to you.

How is premature ejaculation diagnosed, according to the guidelines?

Mainly by talking. All three guidelines base the diagnosis on a medical and sexual history, and none recommends routine blood tests.

  • History. The EAU makes this a strong recommendation: diagnosis should rest on your medical and sexual history, including your own estimate of the time to ejaculation, your sense of control, your distress and any relationship difficulties (EAU). The ISSM accepts the self-estimate of you and your partner as the measure of time in clinical practice (ISSM).
  • Physical exam. The AUA/SMSNA and EAU both include a focused physical examination, mainly to check for erection problems or other causes. The ISSM calls it advisable but not mandatory.
  • Questionnaires. Tools such as the Premature Ejaculation Diagnostic Tool (PEDT) may be used as an aid; the ISSM says they should not replace a detailed history.
  • Tests. The EAU strongly advises against routine laboratory tests unless your history or exam points to something. The AUA/SMSNA says no extra tests for lifelong PE, and tests as appropriate for acquired PE.

So a first appointment for PE is mostly a conversation. Our guide on when to see a doctor lists the questions you are likely to be asked.

What is the first-line treatment for premature ejaculation?

It depends on the guideline and on your type of PE. The table below sets the main recommendations side by side.

TreatmentAUA/SMSNA (US)EAU (Europe)ISSM (international)In plain English
Treat erection problems or another cause firstTreat erectile dysfunction per the ED guideline (Expert Opinion)Treat ED, other sexual problems or prostatitis first (Strong)Combined medical and psychological approach for acquired PEIf something else is driving PE, fix that first
On-demand dapoxetineFirst-line where available (Strong)First-line for lifelong PE (Strong)Supported, level 1aTaken before sex; not available in the US
Daily SSRIs (off-label)First-line (Strong)Second-line (Strong)Supported, level 1aDaily antidepressant at low dose; builds up over weeks
Clomipramine (off-label)First-line, on demand (Strong)Second-line, daily or on demand (Strong)Supported, level 1aOlder antidepressant; more side effects
Numbing sprays and creamsFirst-line (Strong)Lidocaine–prilocaine spray first-line for lifelong PE (Strong)Supported, level 1aApplied before sex; no tablet
Tramadol (off-label)After first-line failure (Conditional)Third-line, with caution (Strong)Only when other therapies have failedOpioid with a risk of dependence
Alpha blockersAfter first-line failure (Expert Opinion)Not in the recommendationsNot in the recommendationsLittle evidence
PDE5 inhibitors without EDNot among its PE recommendations (only for coexisting ED)Alone or combined (Strong)Not recommendedThe guidelines disagree
Behavioral or psychological therapyConsider referral to a sexual health therapist (Moderate)Combined with medication (Weak)Some evidence, level 2bRecommended, mostly alongside medication
Combination of medication and therapyMay be more effective than either alone (Moderate)Recommended in combinationEspecially useful in acquired PEThe approach all three favor

Sources: AUA/SMSNA statements 8 to 13 (AUA); EAU recommendations table (EAU); ISSM recommendations (ISSM).

Two background facts explain much of the difference. First, no medicine is approved by the US Food and Drug Administration for PE, so every US prescription is off-label (Shindel et al., 2022). Second, in Europe dapoxetine and a lidocaine–prilocaine spray are the licensed options, so the EAU puts them first (Salonia et al., 2025). For what each medicine involves, see our neutral comparison of premature ejaculation medication and our guide to dapoxetine.

Lifelong vs acquired PE: different starting points

The EAU states that "pharmacotherapy must be considered the first-line treatment for patients with lifelong PE", whereas treating the underlying cause, such as erectile dysfunction, prostatitis, urinary symptoms, anxiety or an overactive thyroid, must be the initial goal in acquired PE (EAU). This matters because the overlap with erection problems can be large: in one small online survey, 76.3% of men with PE also had erectile dysfunction (defined by questionnaire, mild cases included) (Tsai et al., 2019).

Where do the guidelines disagree?

They disagree on five points, and each has a practical consequence.

  1. The time cut-off for lifelong PE. About 1 minute for the ISSM and EAU, about 2 minutes for the AUA/SMSNA. A man at 90 seconds may meet one definition and not the other.
  2. Dapoxetine. First-line in Europe, unavailable in the US. A US doctor will reach for a daily SSRI, clomipramine or a numbing product instead.
  3. Daily SSRIs. First-line in the US, second-line in Europe, mainly because they are off-label everywhere and dapoxetine is licensed in Europe.
  4. Erection pills for men without erection problems. The AUA/SMSNA mentions them only for men who also have erectile dysfunction, the ISSM does not recommend PDE5 inhibitors for lifelong PE in men with normal erections, while the current EAU edition recommends them alone or in combination. A meta-analysis found they increased latency more than placebo, but most trials were of unclear quality (Martyn-St James et al., 2017). See does Viagra make you last longer?
  5. Injections. The AUA/SMSNA classes bulking injections as experimental, while the EAU allows hyaluronic acid injection "with caution" as a weak recommendation.

What do the guidelines say about behavioral and psychological therapy?

All three include it, and all three favor it alongside medication rather than in competition with it. The AUA/SMSNA advises clinicians to consider referring men with PE to a mental health professional with expertise in sexual health, and to tell them that combining behavioral and drug approaches may be more effective than either alone (AUA). The ISSM finds "some evidence" for psychological and behavioral interventions on their own (ISSM).

The EAU is the most cautious: it calls the evidence for psychosexual interventions alone "weak and inconsistent" and notes that their long-term outcomes are unknown (EAU). A Cochrane review reached a similar verdict, because the trials are few and small (Melnik et al., 2011). The combination evidence is stronger: a 2025 meta-analysis of 8 randomized trials (656 men with lifelong PE) found that adding a non-drug therapy to dapoxetine improved latency and symptom scores more than dapoxetine alone (Nieves Martín et al., 2025).

The EAU also says the long-term outcomes of drug treatments are unknown, and that cumulative discontinuation of dapoxetine reaches 90% two years after starting (EAU). That is one reason a skill that does not depend on a tablet is worth building, whatever else you choose. Our guide to sex therapy for premature ejaculation explains what that route involves.

What do the guidelines say about circumcision, supplements and surgery?

They are skeptical of all three as PE treatments.

  • Circumcision. The AUA/SMSNA advises clinicians to tell patients that ejaculatory latency is not affected by circumcision status (AUA).
  • Alternative therapies and supplements. The AUA/SMSNA says there is insufficient evidence to support them. Our review of supplements looks at the evidence and the safety warnings.
  • Surgery and nerve procedures. The AUA/SMSNA classes surgery, including bulking injections, as experimental and suitable only within an approved clinical trial. The EAU advises against dorsal neurectomy, which cuts penile nerves, because more safety data are needed. The ISSM calls nerve procedures irreversible and says their safety must be established first, and does not recommend penile injections of vasoactive drugs. Our page on whether premature ejaculation can be cured looks at these "permanent fix" claims, and our guide to surgery and procedures for premature ejaculation sets out the trial evidence.

How can you use the guidelines at your appointment?

Use them to ask better questions, not to self-prescribe. Doctors do not always raise sexual health: in the PEPA survey, only 9.0% of men with PE had consulted a doctor, and 81.9% of those had to bring up the subject themselves (Porst et al., 2007).

  1. Know your pattern

    Note whether PE has been there from the start or began later, roughly how long you last, how much control you feel and whether erections are reliable. Our self-assessment produces a short summary.

  2. Ask about causes first

    If PE started later in life, ask whether erection problems, prostate inflammation or thyroid function should be checked. That is the first step in every guideline.

  3. Ask which options are licensed where you live

    Dapoxetine and a lidocaine–prilocaine spray are licensed in Europe; in the US, every medicine is off-label. Ask what that means for side effects and follow-up.

  4. Ask about combining

    All three guidelines support combining medication with behavioral or psychological therapy. Ask whether a referral, a pelvic floor physiotherapist or a structured training plan fits your situation.

  5. Agree on a review date

    Decide together how long to try the plan and what counts as success: more control and less distress, not only more minutes.

The bottom line

The AUA/SMSNA, EAU and ISSM guidelines agree that PE is diagnosed from your history, that erection problems and other causes come first, and that medication, numbing products and behavioral therapy all have a place, ideally combined. They differ on which medicine to try first, largely because dapoxetine is licensed in Europe but not in the US, and on erection pills for men without erection problems. None supports surgery outside research. Bring your pattern, your questions and your preferences, and choose with your doctor.

Frequently asked questions

What is the first-line treatment for premature ejaculation?

It depends on the guideline. The US AUA/SMSNA guideline lists daily SSRIs, on-demand clomipramine or dapoxetine (where available) and numbing products as first-line medicines. The European EAU guideline recommends dapoxetine or a lidocaine–prilocaine spray for lifelong PE, and treating the underlying cause first in acquired PE.

What do the EAU guidelines say about premature ejaculation?

The EAU diagnoses PE from history and a physical exam, advises against routine tests, recommends treating erection problems or prostatitis first, and puts dapoxetine or a lidocaine–prilocaine spray first for lifelong PE, with daily SSRIs or clomipramine second and tramadol third.

Are behavioral techniques recommended by the guidelines?

Yes, mostly as part of a combined approach. The AUA/SMSNA advises that combining behavioral and drug treatment may be more effective than either alone, and the ISSM finds some evidence for psychological and behavioral therapy on its own.

Do the guidelines recommend surgery for premature ejaculation?

No. The AUA/SMSNA calls surgery, including bulking injections, experimental, the EAU advises against dorsal neurectomy, and the ISSM says the safety of nerve procedures still needs to be established.

Why is dapoxetine not first-line in the US?

Because it is not FDA-approved. The AUA/SMSNA lists it as a first-line option only where it is available, and US doctors prescribe other medicines off-label.

Sources

  1. Shindel AW, Althof SE, Carrier S, Chou R, McMahon CG, Mulhall JP, Paduch DA, Pastuszak AW, Rowland D, Tapscott AH, Sharlip ID (2022). Disorders of Ejaculation: An AUA/SMSNA Guideline. The Journal of Urology. Summary · doi:10.1097/JU.0000000000002392
  2. Salonia A, Capogrosso P, Boeri L, Cocci A, Corona G, Dinkelman-Smit M, Falcone M, Jensen CF, Gül M, Kalkanli A, Kadioğlu A, Martinez-Salamanca JI, Afonso Morgado L, Russo GI, Serefoğlu EC, Verze P, Minhas S (2025). European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie's Disease. European Urology. Summary · doi:10.1016/j.eururo.2025.04.010
  3. Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, Becher E, Dean J, Giuliano F, Hellstrom WJ, Giraldi A, Glina S, Incrocci L, Jannini E, McCabe M, Parish S, Rowland D, Segraves RT, Sharlip I, Torres LO (2014). An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). The Journal of Sexual Medicine. Summary · doi:10.1111/jsm.12504
  4. Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, Becher EF, Dean J, Giuliano F, Hellstrom WJ, Giraldi A, Glina S, Incrocci L, Jannini E, McCabe M, Parish S, Rowland D, Segraves RT, Sharlip I, Torres LO (2014). An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. The Journal of Sexual Medicine. Summary · doi:10.1111/jsm.12524
  5. Nieves Martín M, Marín Novoa P, Avendaño-Coy J (2025). Dapoxetine combined with non-pharmacological approaches for lifelong premature ejaculation. A systematic review and meta-analysis. The Journal of Sexual Medicine. Summary · doi:10.1093/jsxmed/qdaf238
  6. Melnik T, Althof S, Atallah AN, Puga ME, Glina S, Riera R (2011). Psychosocial interventions for premature ejaculation. Cochrane Database of Systematic Reviews. Summary · doi:10.1002/14651858.CD008195.pub2
  7. Martyn-St James M, Cooper K, Ren S, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, Hood C (2017). Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. European Urology Focus. Summary · doi:10.1016/j.euf.2016.02.001
  8. Tsai WK, Chiang PK, Lu CC, Jiann BP (2019). The Comorbidity Between Premature Ejaculation and Erectile Dysfunction-A Cross-Sectional Internet Survey. Sexual Medicine. Summary · doi:10.1016/j.esxm.2019.06.014
  9. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J (2007). The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. European Urology. Summary · doi:10.1016/j.eururo.2006.07.004
  10. AUA/SMSNA Guideline: Disorders of Ejaculation (2020)
  11. EAU Guidelines on Sexual and Reproductive Health: Disorders of ejaculation
  12. ISSM guidelines for the diagnosis and treatment of PE, open-access version (Sexual Medicine, 2014)
  13. NHS: Ejaculation problems